DaVita could be weak on Medicare Advantage rates, says Piper Jaffray Piper Jaffray believes shares of DaVita could be weak today following the release of Medicare's Advance Notice for 2015 Medicare Advantage rates, which it says was worse than expected. Piper notes Preliminary 2015 MA rates were down 7.8% versus expectations for a 6%-7% cut. The firm thinks final rates could improve and recommends buying shares of DaVita on any weakness. Piper maintains an Overweight rating on the stock with a $73 price target.
News For DVA From The Last 14 Days
Check below for free stories on DVA the last two weeks.